Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
Journal of the National Cancer Institute|March 25, 2014
ResponseBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 25, 2019
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?Boris Freidlin, Edward L Korn
Journal of the National Cancer Institute|January 9, 2014
A model too farBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|February 5, 2015
Commentary on Hey and KimmelmanEdward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Methodology for comparative effectiveness research: potential and limitationsEdward L Korn, Boris Freidlin
Journal of the National Cancer Institute|April 5, 2017
Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design ElementsEdward L Korn, Boris Freidlin
Pharmacogenomics|December 15, 2010
Biomarker-adaptive clinical trial designsBoris Freidlin, Edward L Korn
Journal of Biopharmaceutical Statistics|October 31, 2017
Quantitative assessment of a prognostic or predictive biomarker panelEdward L Korn, Boris Freidlin
Statistics in Medicine|February 12, 2005
Testing treatment effects in the presence of competing risksBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|January 7, 2022
Time trends with response-adaptive randomization: The inevitability of inefficiencyEdward L Korn, Boris Freidlin
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
Journal of the National Cancer Institute|March 25, 2014
ResponseBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 25, 2019
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?Boris Freidlin, Edward L Korn
Journal of the National Cancer Institute|January 9, 2014
A model too farBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|February 5, 2015
Commentary on Hey and KimmelmanEdward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Methodology for comparative effectiveness research: potential and limitationsEdward L Korn, Boris Freidlin
Journal of the National Cancer Institute|April 5, 2017
Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design ElementsEdward L Korn, Boris Freidlin
Pharmacogenomics|December 15, 2010
Biomarker-adaptive clinical trial designsBoris Freidlin, Edward L Korn
Journal of Biopharmaceutical Statistics|October 31, 2017
Quantitative assessment of a prognostic or predictive biomarker panelEdward L Korn, Boris Freidlin
Statistics in Medicine|February 12, 2005
Testing treatment effects in the presence of competing risksBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|January 7, 2022
Time trends with response-adaptive randomization: The inevitability of inefficiencyEdward L Korn, Boris Freidlin
Pageof 12